GSK plc announced that depemokimab has been accepted for review in China and Japan for asthma and chronic rhinosinusitis with nasal polyps (CRSwNP); if approved, it will be the first ultra-long-acting biologic requiring dosing only every six months. The announcement was made on January 28, 2025, and is based on positive results from trials showing efficacy in reducing symptoms and hospitalizations.